LAS41004 clinical trials
Also written LAS41004.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses LAS41004 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LAS41004
- 4
Studies by the year they started
5 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses LAS41004 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate PsoriasisCompletedPhase 2Almirall, S.A.NCT02180464Written as LAS41004
- Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque TestCompletedPhase 2Almirall, S.A.NCT01360944Written as LAS41004
- Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of PsoriasisCompletedPhase 2Almirall, S.A.NCT01119339Written as LAS 41004
- Clinical Trial to Investigate Efficacy of LAS41004 in PsoriasisCompletedPhase 2Almirall, S.A.NCT01283698Written as Experimental: LAS 41004 dosage 1
- Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque TestCompletedPhase 2Almirall, S.A.NCT01462643Written as LAS41004